Henry Fuchs
Chief Tech/Sci/R&D Officer en BIOMARIN PHARMACEUTICAL INC. .
Fortuna: 17 M $ al 31/03/2024
Perfil
En la actualidad, Henry J. Fuchs ocupa el cargo de Presidente de Investigación y Desarrollo Mundial en BioMarin Pharmaceutical, Inc. El Dr. Fuchs también forma parte del consejo de Mirati Therapeutics, Inc. En su trayectoria profesional anterior ocupó el cargo de director independiente en Ardea Biosciences, Inc., director médico y vicepresidente ejecutivo en Onyx Pharmaceuticals, Inc. y director en Genentech, Inc. El Dr. Fuchs se doctoró en la Universidad George Washington y se licenció en la Universidad de Harvard.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
15/03/2024 | 196 872 ( 0.10% ) | 17 M $ | 31/03/2024 |
Cargos activos de Henry Fuchs
Empresas | Cargo | Inicio |
---|---|---|
BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 01/03/2009 |
Antiguos cargos conocidos de Henry Fuchs.
Empresas | Cargo | Fin |
---|---|---|
MIRATI THERAPEUTICS | Director/Board Member | 11/05/2023 |
GENOMIC HEALTH, INC. | Director/Board Member | 08/11/2019 |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Chief Executive Officer | 01/06/2005 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Tech/Sci/R&D Officer | 01/12/2008 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/1996 |
Formación de Henry Fuchs.
Harvard University | Undergraduate Degree |
George Washington University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
Empresas privadas | 6 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Genomic Health, Inc.
Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Ardea Biosciences, Inc.
Ardea Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ardea Biosciences, Inc. is a biotechnology company which is focused on the development of small-molecule therapeutics for the treatment of serious diseases. The company was founded in January 1994 and is headquartered in Wilmington, DE. | Health Technology |
- Bolsa de valores
- Insiders
- Henry Fuchs